<div id="preview-section-abstract"> <div class="Abstracts u-font-serif" id="abstracts"> <div class="abstract author" id="ab0005" lang="en"> <h2 class="section-title u-h3 u-margin-l-top u-margin-xs-bottom">Abstract</h2> <div id="as0005"> <h3 class="u-h4 u-margin-m-top u-margin-xs-bottom" id="st0010">Background</h3> <p id="sp0060"><span>Although current guidelines recommend <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/antithrombotic" title="Learn more about oral anticoagulants from ScienceDirect's AI-generated Topic Pages">oral anticoagulants</a> (OAC) with or without <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/antiplatelet" title="Learn more about antiplatelet from ScienceDirect's AI-generated Topic Pages">antiplatelet</a> therapy (APT) following <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/percutaneous-aortic-valve-replacement" title="Learn more about transcatheter aortic valve replacement from ScienceDirect's AI-generated Topic Pages">transcatheter aortic valve replacement</a> (TVAR) in patients with an indication for long-term <a href="https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/anticoagulation" title="Learn more about anticoagulation from ScienceDirect's AI-generated Topic Pages">anticoagulation</a> therapy, the optimal antithrombotic strategy remains unknown in these population. Herein, we conducted a meta-analysis comparing the outcome of OAC alone versus OAC with APT following TAVR in patients with </span><a href="https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/atrial-fibrillation" title="Learn more about atrial fibrillation from ScienceDirect's AI-generated Topic Pages">atrial fibrillation</a><span> </span>(AF).</p> </div> <div id="as0010"> <h3 class="u-h4 u-margin-m-top u-margin-xs-bottom" id="st0015">Methods</h3> <p id="sp0065">MEDLINE and EMBASE were searched through May 2020 to identify clinical trials that investigated OAC alone versus OAC with APT following TAVR in patients with AF. From each study, we extracted the hazard ratios (HRs) or risk ratios of major or life threatening bleeding, stroke, all-cause mortality and<span> </span><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/cardiovascular-mortality" title="Learn more about cardiovascular mortality from ScienceDirect's AI-generated Topic Pages">cardiovascular mortality</a>.</p> </div> <div id="as0015"> <h3 class="u-h4 u-margin-m-top u-margin-xs-bottom" id="st0020">Results</h3> <p id="sp0070">1 randomized controlled trial and 3 observational studies were identified, which enrolled a total of 2032 patients with AF who underwent TAVR assigned to the OAC group (<em>n</em> = 722) or OAC with APT group (<em>n</em> = 1310). Pooled analyses demonstrated the rate of major or life threatening bleeding was significantly lower in the OAC group compared to the OAC with APT group (HR [95% Confidence Interval [CI] = 0.54 [0.38–0.77],<span> </span><em>P</em> = .0006]). However, the rate of stroke was similar in both groups (HR [95% CI] = 1.22 [0.80–1.87],<span> </span><em>P</em> = .36). All-cause and cardiovascular mortalities were also similar in both groups.</p> </div> <div id="as0020"> <h3 class="u-h4 u-margin-m-top u-margin-xs-bottom" id="st0025">Conclusions</h3> <p id="sp0075">We observed that OAC with APT following TAVR in patients with AF increased the risk of bleeding compared to OAC alone without decreasing the risk of stroke.</p> </div> </div> </div> </div> <div id="preview-section-introduction"></div>